Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

23 Mar 2020

Abstract excerpt

Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening infectious complications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technologies, several novel prophylactic agents, and further improvements in preemptive therapy and treatment of established CMV disease. Treatment decisions for CMV reactivation are becoming increasingly difficult...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments
Share to Parvovirus B19 Infection Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32202631
DOI: 10.1182/blood.2019000956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantationPMID 32202631Read ↗

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.Semantic proximity Read ↗

American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy RecipientsSemantic proximity Read ↗

Epidemiology, clinical outcomes, and treatment patterns of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation in China: a scoping review and meta-analysisSemantic proximity Read ↗

Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantationSemantic proximity Read ↗

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experienceSemantic proximity Read ↗

HCMV control in allogeneic stem cell transplant recipients - an analysis of humoral and cellular players beyond antigen-specific T cells in the letermovir eraSemantic proximity Read ↗

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

Viral reactivations following hematopoietic stem cell transplantation in pediatric patients – A single center 11-year analysisSemantic proximity Read ↗

Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCTSemantic proximity Read ↗

"Unusual" viral diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, retrospective studySemantic proximity Read ↗

Revealing the Unseen: Next-Generation Sequencing for Early Detection of Drug-Resistant Cytomegalovirus Variants Upon Letermovir Prophylaxis FailureSemantic proximity Read ↗

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.